Fortress Biotech Inc (NAS:FBIO)
$ 1.76 0.06 (3.53%) Market Cap: 33.86 Mil Enterprise Value: 36.44 Mil PE Ratio: 0 PB Ratio: 1.18 GF Score: 50/100

Fortress Biotech Inc at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 15, 2023 / 04:40PM GMT
Release Date Price: $10.83 (+0.98%)
Unidentified Analyst

Hey, everyone. Thank you so much for joining us for the Annual Oppenheimer Healthcare Conference. My name is Alex. I work with Mark Breidenbach in the biotech department.

Joining me today is Fortress Biotech and presenting is Dr. Lindsay Rosenwald. He'll be giving us a little -- some updates about his company. Just a quick refresher, Fortress, they're a clinical-stage biopharma company. They work on both identification and development of potential marketed drugs. They have a very diverse portfolio of all sorts of drugs from preclinical to commercial-stage assets.

And I'm going to pass it off to Dr. Rosenwald to give us more information about everything that they're working on.

Lindsay Rosenwald
Fortress Biotech, Inc. - Chairman, President & CEO

Thanks, Alex. Appreciate it. And thanks, everybody, for watching the Fortress Biotech presentation at Oppenheimer. And certainly, thanks to everybody -- Oppenheimer to putting this together.

So Fortress -- first of all, get my lawyers out of the way. We're making forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot